These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 22425914)

  • 1. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
    Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer.
    Meek CL; Wallace AM; Forrest LM; McMillan DC
    Clin Nutr; 2010 Apr; 29(2):206-9. PubMed ID: 19748165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
    Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
    J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
    Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
    Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.
    Forrest LM; McMillan DC; McArdle CS; Angerson WJ; Dagg K; Scott HR
    Br J Cancer; 2005 May; 92(10):1834-6. PubMed ID: 15870712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer.
    Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kunizaki M; Taniguchi D; Nagayasu T
    Eur J Cardiothorac Surg; 2015 Apr; 47(4):e140-5. PubMed ID: 25548132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer.
    Yotsukura M; Ohtsuka T; Kaseda K; Kamiyama I; Hayashi Y; Asamura H
    J Thorac Oncol; 2016 Aug; 11(8):1311-1318. PubMed ID: 27234603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
    Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
    Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.
    Denehy L; Hornsby WE; Herndon JE; Thomas S; Ready NE; Granger CL; Valera L; Kenjale AA; Eves ND; Jones LW
    J Thorac Oncol; 2013 Dec; 8(12):1545-50. PubMed ID: 24389436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
    Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
    Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
    Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
    PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
    Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
    Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
    Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
    Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
    Jiang AG; Lu HY
    J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
    Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.